Schering-Plough Gyne-Lotrimin
Executive Summary
Reportedly surpasses 1990 sales in the first two months since the anti-fungal made the prescription-to-OTC switch. In its 1990 annual report, released March 12, Schering-Plough predicts first-year sales of over $100 mill. for the product. The company said at the time of the switch that Gyne-Lotrimin generated about $21 mil. in prescription sales ("The Pink Sheet" Dec. 10, T&G-7).